Prometheus Biosciences
Committed to the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune disease. Learn more
Launch date
Employees
Market cap
AUD14.8b
Enterprise valuation
AUD13.7b (Public information from Jun 2023)
Share price
$199.92 RXDX
San Diego California (HQ)
Authorizing premium user...